重症监护诊断市场－全球产业规模、份额、趋势、机会和预测（按测试类型、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球重症监护诊断市场价值为 13.3 亿美元，预计在预测期内将大幅成长，到 2030 年的复合年增长率为 5.11%。由于重症监护环境中对快速精确诊断工具的需求不断增长，这个市场正在快速发展。随着全球慢性病的增加和人口老化，败血症、心臟病、呼吸系统疾病和器官衰竭等急性疾病的盛行率正在迅速上升。这种增长凸显了能够早期发现和有效干预的先进诊断技术的必要性。例如，美国 65 岁及以上人口预计将从 2022 年的 5,800 万增加到 2050 年的 8,200 万，占总人口的比例从 17% 增长到 23%，这表明人口结构的急剧变化加剧了对重症监护服务的需求。

市场概览
预测期	2026-2030
2024年市场规模	13.3亿美元
2030年市场规模	17.8亿美元
2025-2030 年复合年增长率	5.11%
成长最快的领域	流式细胞仪
最大的市场	北美洲

关键市场驱动因素

重大疾病发生率上升

主要市场挑战

高级诊断的费用

主要市场趋势

分子诊断的进展

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球重症监护诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按测试类型（流式细胞仪、血液学测试、微生物学和感染性测试、凝血测试、免疫蛋白、常规和特殊化学等）
  • 按最终使用者（手术室、急诊室、重症监护室等）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美重症监护诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲重症监护诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太重症监护诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲重症监护诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲重症监护诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购

第 13 章：全球重症监护诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代治疗类型的威胁

第 15 章：竞争格局

• Neoplas med GmbH
• US Medical Innovations
• Terumo Medical Corp
• Adtec Plasma Technology Co Ltd
• Apyx Medical Corp
• Nordson Corp
• Europlasma NV
• Terraplasma GmbH
• Henniker Plasma
• Smith & Nephew plc

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Critical Care Diagnostics Market was valued at USD 1.33 billion in 2024 and is projected to grow significantly during the forecast period with a CAGR of 5.11% through 2030F. This market is rapidly evolving, driven by an increasing need for prompt and precise diagnostic tools in critical care environments. With a global rise in chronic diseases and an aging population, the prevalence of acute conditions such as sepsis, cardiac disorders, respiratory diseases, and organ failure is climbing rapidly. This growth underscores the necessity for advanced diagnostics capable of early detection and efficient intervention. For example, the U.S. population aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, growing from 17% to 23% of the total population, illustrating a sharp demographic shift that intensifies demand for critical care services.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.33 Billion
Market Size 2030	USD 1.78 Billion
CAGR 2025-2030	5.11%
Fastest Growing Segment	Flow Cytometry
Largest Market	North America

Key Market Drivers

Increasing Incidence of Critical Illnesses

A major driver of growth in the critical care diagnostics market is the rising occurrence of severe medical conditions globally. As populations continue to age and lifestyle patterns evolve, conditions such as sepsis, cardiac and respiratory disorders, and organ failure are becoming more widespread. This has amplified the demand for cutting-edge diagnostic technologies that enable swift and accurate identification of these illnesses. Timely diagnosis is essential in critical care as it facilitates early intervention, thereby improving patient recovery and survival rates. According to the World Health Organization (WHO), approximately 422 million individuals were living with diabetes in 2023, predominantly in low- and middle-income countries. With around 1.5 million annual deaths directly attributed to diabetes, the need for early detection and effective management solutions is particularly pressing in resource-limited settings.

Key Market Challenges

Cost of Advanced Diagnostics

One of the foremost challenges in the critical care diagnostics market is the high cost associated with advanced diagnostic technologies. The growing prevalence of life-threatening health conditions, including sepsis, cardiac and respiratory diseases, and organ failure, is fueling the demand for these innovations. However, the financial burden of acquiring and maintaining such sophisticated diagnostic equipment is considerable. This poses a challenge particularly for healthcare providers operating in resource-constrained regions. Additionally, the aging global population adds further pressure on healthcare systems, making cost-effectiveness a crucial factor in the adoption of diagnostic solutions, especially in public and rural healthcare settings.

Key Market Trends

Advancements in Molecular Diagnostics

Technological progress in molecular diagnostics is shaping a key trend in the critical care diagnostics landscape. This approach analyzes genetic material and other molecular indicators to identify diseases, pathogens, or mutations with high precision. The deeper understanding of genetic factors in disease development has allowed for more accurate and personalized diagnostic techniques. Molecular diagnostics enables detection of illnesses at a cellular level, thereby improving diagnostic accuracy and facilitating tailored treatment plans based on individual genetic profiles. This innovation is redefining diagnostic capabilities in critical care by enhancing both speed and specificity of disease identification.

Key Market Players

• Neoplas med GmbH
• U.S. Medical Innovations
• Terumo Medical Corp
• Adtec Plasma Technology Co Ltd
• Apyx Medical Corp
• Nordson Corp
• Europlasma NV
• Terraplasma GmbH
• Henniker Plasma
• Smith & Nephew plc

Report Scope:

In this report, the Critical Care Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Critical Care Diagnostics Market, Test Type:

• Flow Cytometry
• Hematology Test
• Microbiology and Infectious Test
• Coagulation Test
• Immunoprotein
• Routine and Special Chemistry
• Others

Critical Care Diagnostics Market, End User:

• Operating Room
• Emergency Room
• Intensive Care Unit
• Other

Critical Care Diagnostics Market, By Region:

• North America

United States

Canada

Mexico

• Europe

Germany

United Kingdom

Italy

France

Spain

• Asia Pacific

China

India

Japan

South Korea

Australia

• South America

Brazil

Argentina

Colombia

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Critical Care Diagnostics Market.

Available Customizations:

Critical Care Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Critical Care Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Flow Cytometry, Hematology Test, Microbiology and Infectious Test, Coagulation Test, Immunoprotein, Routine, and Special Chemistry, and Others)
  • 5.2.2. By End User (Operating Room, Emergency Room, Intensive Care Unit, and Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Critical Care Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Critical Care Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Critical Care Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Critical Care Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By End User

7. Europe Critical Care Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Critical Care Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Critical Care Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Critical Care Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Critical Care Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Critical Care Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Critical Care Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Critical Care Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Critical Care Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Critical Care Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Critical Care Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Critical Care Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By End User

9. South America Critical Care Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Critical Care Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Critical Care Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Critical Care Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Critical Care Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Critical Care Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Critical Care Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Critical Care Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Critical Care Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Neoplas med GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. U.S. Medical Innovations
• 15.3. Terumo Medical Corp
• 15.4. Adtec Plasma Technology Co Ltd
• 15.5. Apyx Medical Corp
• 15.6. Nordson Corp
• 15.7. Europlasma NV
• 15.8. Terraplasma GmbH
• 15.9. Henniker Plasma
• 15.10. Smith & Nephew plc

16. Strategic Recommendations

17. About Us & Disclaimer